All In Biotech

Drug Trial Radar · NCT04866134

A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1b/2, Open-label, Multi-center Study of ERAS-007 (ERK Inhibitor) Administered as Monotherapy or in Combination With ERAS-601 (SHP2 Inhibitor) in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1)

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

May 7, 2021

Primary completion

Jul 1, 2026

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
First posted
Apr 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. * To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • ERAS-007Drug

    ERAS-007 will be administered orally as specified in Arm description.

  • ERAS-601Drug

    ERAS-601 will be administered orally as specified in Arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QWTime frame: Assessed up to 24 months from time of first dose
  2. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
  3. Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 29
  4. Recommended dose (RD)Time frame: Study Day 1 up to Day 29
  5. Adverse EventsTime frame: Assessed up to 24 months from time of first dose
  6. Plasma concentration (Cmax)Time frame: Study Day 1 up to Day 29
  7. Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to Day 29
  8. Area under the curveTime frame: Study Day 1 up to Day 29
  9. Half-lifeTime frame: Study Day 1 up to Day 29

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute (HealthONE)

    Denver, Colorado

  • Sarah Cannon Research Institute (Florida Cancer Specialists)

    Sarasota, Florida

  • Sarah Cannon Research Institute (Tennessee Oncology)

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • NEXT Oncology

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.